CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 72 enrolled
Drug / intervention
Lisprodrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01159938
NCT01159938Phase 4Completed

The Effect of Postprandial Hyperglycemia on the Arterial Stiffness in Patients With Type 2 Diabetes

Eli Lilly and Company·interventional·Posted Jul 12, 2010·Updated Apr 3, 2014

In Brief

A Phase 4 clinical trial evaluating Lispro for Diabetes Mellitus, Type 2. Completed, enrolled 72 participants across 1 site.

Detailed Summary

This Study is looking at whether high blood glucose levels after a meal affect arterial stiffness more or less than low blood glucose levels, and whether certain cardiovascular markers influence the outcome of this.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFinland
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 12, 2010
Enrollment StartOct 1, 2010
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 16.0 years ago

Interventions

Lisprodrug

Dosage based on participants with type 2 diabetes mellitus (T2DM) normal morning insulin dose and energy content of participant's normal breakfast. Subcutaneous injection given on one occasion. Administered once on low post prandial day.